Revolution Medicines (RVMD) has seen its stock soar nearly 100% this year and approximately 285% over the past 12 months, fueled by promising advancements in its drug development for RAS-addicted cancers like pancreatic and lung cancer. Their leading candidate, daraxonrasib, has shown strong phase 3 trial results, significantly improving overall survival in metastatic pancreatic cancer patients compared to standard chemotherapy. However, while the company’s potential is high—with estimates suggesting that daraxonrasib could generate up to $8.5 billion annually—there are risks. The company’s lack of revenue and a lofty market valuation of $33.6 billion raise concerns about sustainability. Any setbacks in clinical trials could sharply impact the stock’s value, making it a risky investment proposition. Investors might consider waiting for a market pullback before investing.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/investing/2026/06/05/revolution-medicines-is-up-97-this-year-here-are-t/
